Lifestyle
ICMR Licenses SHetA2 to Emcure: Could This Drug Replace Surgery for Stage 0 Cervical Cancer?
ICMR has licensed the anti-HPV drug candidate SHetA2 to Emcure Pharmaceuticals. The therapy could offer a non-surgical treatment for stage…
1 stories
ICMR has licensed the anti-HPV drug candidate SHetA2 to Emcure Pharmaceuticals. The therapy could offer a non-surgical treatment for stage…
The stories that matter, in your inbox by 8 AM. Free, no spam.